文献速递心脑血管急症

替奈普酶与阿替普酶治疗急性缺血性卒中的短期安全性和有效性

Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.
PubMed 文献 · JAMA Netw Open · 2025-03-03
一句话结论全国登记数据显示,急性缺血性卒中发病4.5小时内静脉溶栓,替奈普酶与阿替普酶在功能独立和症状性颅内出血上无显著差异。

该比较有效性研究利用2020年7月1日至2022年6月30日前瞻性收集的Get With The Guidelines-Stroke登记数据,纳入发病4.5小时内接受静脉替奈普酶或阿替普酶治疗的连续缺血性卒中患者79 550例,其中替奈普酶9 465例(11.9%)、阿替普酶70 085例(88.1%)。主要终点出院时功能独立(mRS 0-2)在两组间无显著差异(AOR 1.00,95%CI 0.93-1.07),症状性颅内出血(AOR 0.96,95%CI 0.83-1.11)和院内死亡或临终关怀出院(AOR 0.98,95%CI 0.89-1.07)亦无显著差异。在适合但未行血管内取栓的患者中,替奈普酶组出院回家(AOR 1.26,95%CI 1.03-1.53)、院内死亡(AOR 0.63,95%CI 0.47-0.85)及院内死亡或临终关怀出院复合终点(AOR 0.78,95%CI 0.62-0.97)有显著改善。作者认为替奈普酶是阿替普酶的合理替代选择。

要点

  • 发病4.5小时内静脉溶栓的急性缺血性卒中患者中,替奈普酶与阿替普酶出院时功能独立(mRS 0-2)无显著差异:AOR 1.00(95%CI 0.93-1.07)。
  • 症状性颅内出血(36小时内)两组无显著差异:替奈普酶 vs 阿替普酶 AOR 0.96(95%CI 0.83-1.11)。
  • 院内死亡或临终关怀出院两组无显著差异:AOR 0.98(95%CI 0.89-1.07)。
  • 适合但未行血管内取栓的患者中,替奈普酶组出院回家(AOR 1.26,95%CI 1.03-1.53)、院内死亡(AOR 0.63,95%CI 0.47-0.85)及院内死亡或临终关怀出院复合终点(AOR 0.78,95%CI 0.62-0.97)有显著改善。
  • 作者结论支持替奈普酶作为阿替普酶的合理替代选择。

适用人群与场景

  • 发病4.5小时内(自最后已知正常时间起)接受静脉替奈普酶或阿替普酶治疗的连续缺血性卒中患者,数据来自Get With The Guidelines-Stroke登记,采集时间2020年7月1日至2022年6月30日。

研究设计与关键结果

  • 研究类型为比较有效性研究,使用2020年7月1日至2022年6月30日前瞻性收集的Get With The Guidelines-Stroke登记数据,纳入79 550例发病4.5小时内接受静脉溶栓的缺血性卒中患者。
  • 总体人群平均(SD)年龄68.6(14.8)岁,女性38 596例(48.5%),NIHSS评分中位数7(IQR 4-13);替奈普酶组9 465例(11.9%),平均(SD)年龄69.6(14.7)岁,NIHSS中位数7(IQR 4-14),女性4 504例(47.6%);阿替普酶组70 085例(88.1%),平均(SD)年龄68.5(14.8)岁,NIHSS中位数7(IQR 4-13),女性34 092例(48.6%)。
  • 校正协变量后,总体队列中替奈普酶与阿替普酶在出院时功能独立(mRS 0-2)无显著差异:AOR 1.00(95%CI 0.93-1.07)。
  • 总体队列中症状性颅内出血(36小时内)无显著差异:AOR 0.96(95%CI 0.83-1.11)。
  • 总体队列中院内死亡或临终关怀出院无显著差异:AOR 0.98(95%CI 0.89-1.07)。
  • 在适合但未行血管内取栓的患者中,替奈普酶组出院回家有显著改善:AOR 1.26(95%CI 1.03-1.53)。
  • 在适合但未行血管内取栓的患者中,替奈普酶组院内死亡有显著改善:AOR 0.63(95%CI 0.47-0.85)。
  • 在适合但未行血管内取栓的患者中,替奈普酶组院内死亡或临终关怀出院复合终点有显著改善:AOR 0.78(95%CI 0.62-0.97)。

证据类型、等级与局限

  • 证据类型:比较有效性研究,使用Get With The Guidelines-Stroke登记的前瞻性收集数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于发病4.5小时内接受静脉溶栓的急性缺血性卒中患者,本研究支持替奈普酶作为阿替普酶的合理替代选择(作者结论)。
  • 在适合但未行血管内取栓的患者中,替奈普酶组出院回家、院内死亡及院内死亡或临终关怀出院复合终点有显著改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.

OBJECTIVE: To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.

DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.

EXPOSURE: Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.

MAIN OUTCOMES AND MEASURES: The primary end point was functional independence on discharge (modified Rankin Scale [mRS] score, 0-2). Secondary effectiveness end points included disability free at discharge (mRS score, 0-1), discharge home, and independent ambulation at discharge. Safety end points included symptomatic intracranial hemorrhage (sICH) within 36 hours and combined in-hospital mortality or hospice discharge. Generalized linear mixed models were fit to evaluate associations between exposure to tenecteplase (vs alteplase) and end points after adjustment for demographic, clinical, and hospital-level variables. Adjusted odds ratios (AORs) with 95% CIs were computed.

RESULTS: Among 79 550 patients treated with intravenous thrombolysis, the mean (SD) age was 68.6 (14.8) years, 38 596 (48.5%) were female, and the median National Institutes of Health Stroke Scale (NIHSS) score was 7 (IQR, 4-13). Of these patients, 9465 (11.9%) received tenecteplase (mean [SD] age, 69.6 [14.7] years; median NIHSS score, 7 [IQR, 4-14]; 4504 [47.6%] female) and 70 085 (88.1%) received alteplase (mean [SD] age, 68.5 [14.8] years; median NIHSS score, 7 [IQR, 4-13]; 34 092 [48.6%] female). After adjustment for covariates, no significant differences were found between tenecteplase and alteplase in effectiveness or safety outcomes for the overall cohort, including functional independence at discharge (AOR, 1.00; 95% CI, 0.93-1.07), sICH (AOR, 0.96; 95% CI, 0.83-1.11), and in-hospital mortality or hospice discharge (AOR, 0.98; 95% CI, 0.89-1.07), but significant improvement was found in discharge home (AOR, 1.26; 95% CI, 1.03-1.53), in-hospital mortality (AOR, 0.63; 95% CI, 0.47-0.85), and composite in-hospital mortality or hospice discharge (AOR, 0.78; 95% CI, 0.62-0.97) among those who were eligible for but did not undergo endovascular thrombectomy.

CONCLUSIONS AND RELEVANCE: This large, nationwide comparative effectiveness study using data from routine clinical practice demonstrated similar effectiveness and safety outcomes with tenecteplase compared with alteplase in patients with acute ischemic stroke. This study supports tenecteplase as a reasonable alternative to alteplase.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Rousseau JF, Weber JM, Alhanti B, et al. Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke. JAMA Netw Open. 2025. PMID: 40072434. doi:10.1001/jamanetworkopen.2025.0548

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。